Unique technology, Unique market
Xspray Pharma’s unique technology could improve the quality of life, and make it possible for more patients to access improved Protein Kinase Inhibitor (PKI) drugs for treatment of cancer.
-
Latest report
Year End Report 2023 -
Subscribe
Get our latest press releases and reports
Press releases
Regulatory press release 2024-02-14
Interim Report Fourth Quarter 2023
Regulatory press release 2024-02-12
FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July
Regulatory press release 2024-02-07
Xspray Pharma appoints Michael af Winklerfelt as acting CFO
Regulatory press release 2023-12-29
New number of shares and votes in Xspray Pharma
Regulatory press release 2023-12-01
Xspray Pharma raises SEK 92.3 million through warrants TO5
Xspray Pharma uses its innovative, patented technology to develop amorphous product candidates that are improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Often the original companies have secondary patents that are based on the crystalline forms of the active substance. Since Xspray Pharma’s products are amorphous, they can be marketed as soon as the original companies’ drug substance patents expire. This is a unique opportunity for a favorable market establishment on a multi billion dollar market.
We see a large potential for our product portfolio. Our technology is compatible for most of the more than 80 US markeded protein kinase inhibitors. The company’s new porduct candidates are being developed in the same manner as the company´s initial product, XS004 dasatinib. The process is reproducible and reduces the effective developing time for future products in our pipeline. This is an exciting time! Per Andersson, CEO